Abstracts Archive - Page 1244 of 2607 - ACR Meeting Abstracts

Abstract Number: 865 • 2018 ACR/ARHP Annual Meeting
Structural and Microstructural Intraarticular Bone Changes at the Metacarpal Heads in Patients with Psoriatic Arthritis Compared to Controls: A HR-pQCT Study
Dongze Wu¹, James F Griffith², Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Lin Shi³, Edmund Li¹, Isaac T. Cheng¹, Tena K. Li¹, Tracy Y. Zhu⁴, Vivian W. Hung⁴, Ling Qin⁵ and Lai-Shan Tam⁶, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ³Research Centre for Medical Image Computing, Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁵Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Metacarpal head directly exposed to intra-articular inflammatory milieu, therefore may lead to abnormal bone remodeling (bone loss and new bone formation). The aims of…
Abstract Number: 866 • 2018 ACR/ARHP Annual Meeting
Patterns of Monosodium Urate Deposition on Dual-Energy CT in Gout Patients on Urate-Lowering Therapy
Chio Yokose¹, Yuqing Zhang², Nicola Dalbeth³, Jie Wei¹, Savvas Nicolaou⁴, Scott Baumgartner⁵, Jia Hu⁶, Maple Fung⁵ and Hyon K. Choi¹, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ³University of Auckland, Auckland, New Zealand, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada, ⁵Formerly Ardea Biosciences, San Diego, CA, ⁶Heron Therapeutics, San Diego, CA
Background/Purpose: Gout is typically characterized as an acute monoarthritis involving the joints of the foot. However, polyarticular involvement develops, especially in advanced disease. Patterns of…
Abstract Number: 867 • 2018 ACR/ARHP Annual Meeting
An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression – Results from the Imagine-RA Randomized Controlled Trial
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Bo Jannik Ejbjerg³, Daniel Glinatsi⁴, Merete Lund Hetland¹, Lykke Ørnbjerg¹, Jakob M. Møller⁵, Mikael Boesen⁶, Robin Christensen⁷, Kristian Stengaard-Pedersen⁸, Ole Rintek Madsen⁹, Bente Jensen¹⁰, Jan Alexander Villadsen¹¹, Ellen-Margrethe Hauge⁸, Philip Bennett¹², Oliver Hendricks², Karsten Asmussen¹³, Marcin Ryszard Kowalski¹⁴, Hanne Lindegaard¹⁵, Sabrina Mai Nielsen⁷, Henning Bliddal¹⁶, Niels Steen Krogh¹⁷, Torkell Ellingsen¹⁵, Agente Nielsen¹⁸, Lone Balding¹⁹, Anne Grethe Jurik²⁰, Henrik S Thomsen¹⁹ and Mikkel Østergaard²¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²King Christian 10th Hospital for Rheumatic Diseases, University of Southern Denmark, Institute of Regional Health Research, Graasten, Denmark, ³Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ⁴Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ⁵Dept. of Radiology, Copenhagen University Hospitals, Herlev and Gentofte, Copenhagen, Denmark, ⁶Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Hellerup, Denmark, ¹⁰Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ¹¹Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, ¹²Department of Rheumatology, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark, ¹³Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹⁴Department of Rheumatology, Sygehus Vendsyssel, Hjørring, Hjørring, Denmark, ¹⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁶The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ¹⁷The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Radiology, Silkeborg Hospital, Silkeborg, Denmark, ¹⁹Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, ²⁰Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark
Background/Purpose: Magnetic Resonance Imaging (MRI) bone marrow edema (BME)/osteitis and MRI synovitis have been identified as predictors of structural damage progression in rheumatoid arthritis RA1,2.…
Abstract Number: 868 • 2018 ACR/ARHP Annual Meeting
International Multi-Reader Validation of the Outcome Measures in Rheumatology Hip MRI Scoring System (OMERACT HIMRISS) for Bone Marrow Lesions in Osteoarthritis
Jacob L. Jaremko¹, Robert G. Lambert², Susanne J Pedersen³, Ulrich Weber⁴, Duncan Lindsay⁵, Zeid Al-Ani⁵, Marcus Pianta⁶, Stephanie Wichuk⁷, Kieran Steer⁸, Joel Paschke⁹ and Walter P. Maksymowych¹⁰, ¹Radiology, University of Alberta, Edmonton, Canada, Edmonton, AB, Canada, ²Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ³Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴University of Southern Denmark, Odense, Denmark, ⁵Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁶Rheumatology, St. Vincent's Hospital, Melbourne, Australia, ⁷Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ⁸Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁹CaRE Arthritis, Edmonton, Canada, Edmonton, AB, Canada, ¹⁰CaRE Arthritis, Edmonton, AB, Canada
Background/Purpose: Bone marrow lesion (BML) in hip osteoarthritis (OA) may be a determinant of prognosis and a target for emerging anti-inflammatory therapies. We developed the…
Abstract Number: 869 • 2018 ACR/ARHP Annual Meeting
Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout
Fernando Perez-Ruiz^1,2,3, Pascal Richette^4,5, Austin Stack⁶, Ravichandra Karra Gurunath⁷, MARIA JESUS GARCIA DE YEBENES Y PROUS⁸ and Loreto Carmona⁹, ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²University of the Basque Country (UPV/EHU), Bilbao, Spain, ³BioCruces Health Research Institute, Barakaldo, Spain, ⁴Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁵Rheumatology, Université Paris Diderot, Paris, France, ⁶Nephrology, University Hospital Limerick & Health Research Institute,University of Limerick, Limerick, Ireland, ⁷Grünenthal GmbH, Aachen, Germany, ⁸Institute for Musculoskeletal Health, Madrid, Spain, ⁹Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain
Background/Purpose: Gout is associated with an increased risk of cardiovascular events and death. It has been shown that both overall and risk of death are…
Abstract Number: 870 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Burden of Gout in 2017 from the United States
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout is reported to impact 3.9% of the US adult population (Zhu. Arthritis Rheum 2011;63:3136-41). Treatment encompasses controlling acute attacks (flares) and, dependent on…
Abstract Number: 871 • 2018 ACR/ARHP Annual Meeting
Estimates of Diet Quality Explain Less Variability in Serum Urate Levels Than Genetic Factors
Tanya J. Major¹, Ruth Topless¹, Nicola Dalbeth² and Tony R. Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Hyperuricaemia (elevated serum urate) is a central risk factor for gout, an acute inflammatory form of arthritis. The balance between the hepatic production of…
Abstract Number: 872 • 2018 ACR/ARHP Annual Meeting
Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study
Douglas C.A. Taylor¹, Dena Jaffe², Moshe Hoshen³, Galit Shefer³, Asaf Bachrach³, Becca Feldman³, An-Chen Fu¹ and Hyon K. Choi⁴, ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²Kantar Health, Tel Aviv, Israel, ³Clalit Research Institute, Tel Aviv, Israel, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Many studies have found that serum uric acid (sUA) levels are associated with the incidence of chronic kidney disease (CKD), cardiovascular disease (CVD), and…
Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Kenneth Saag¹, Michael A. Becker², William B. White³, Andrew Whelton⁴, Jeffrey Borer⁵, Philip Gorelick⁶, Barbara Hunt⁷, Majin Castillo⁷ and Lhanoo Gunawardhana⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago Pritzker School of Medicine, Chicago, IL, ³Cardiology, University of Connecticut School of Medicine, Farmington, CT, ⁴Johns Hopkins University School of Medicine, Hunt Valley, MD, ⁵State University of New York Downstate Medical Center, Brooklyn, NY, ⁶Michigan State University College of Human Medicine, Grand Rapids, MI, ⁷Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…
Abstract Number: 874 • 2018 ACR/ARHP Annual Meeting
Preventing a Large Majority of Incident Gout Cases By Modifying Key Risk Factors: Findings from a Prospective Cohort of 44,629 Men over 26 Years
Sharan K. Rai^1,2, Na Lu³, Chio Yokose⁴ and Hyon K. Choi^3,4, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Graduate School of Arts and Sciences, Harvard University, Cambridge, MA, ³Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Many modifiable risk factors have been found to be independently associated with the risk of developing gout, including dietary factors (e.g., intakes of red…
Abstract Number: 875 • 2018 ACR/ARHP Annual Meeting
Anti-Calreticulin Antibody – a Novel Antibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy
He Chen^1,2, Guochun Wang³ and Xin Lu⁴, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ²Graduate School of Peking Union Medical College, Beijing, China, ³China-Japan Friendship Hospital, Beijing, China, ⁴Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To investigate the occurrence of anti-calreticulin antibodies (anti-CRT Abs) and evaluate its association with malignancy in patients with idiopathic inflammatory myopathies (IIM). Methods: In…
Abstract Number: 876 • 2018 ACR/ARHP Annual Meeting
Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease
Tori Nault¹, Alex Tsoi², Tamra J. Reed³, Mehrnaz Gharaee-Kermani³, Lori Lowe⁴, Johann Gudjonsson⁴ and Michelle Kahlenberg³, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Dermatomyositis (DM) is a rare disease with both cutaneous and muscle pathophysiology. In the skin of DM patients, very little is known about the…
Abstract Number: 877 • 2018 ACR/ARHP Annual Meeting
Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease
Satoshi Takanashi¹, Naoshi Nishina², Maho Nakazawa², Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatoloy, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of serious organ involvements in idiopathic inflammatory myositis. Krebs von den Lungen-6 (KL-6) is an antigen produced primarily…
Abstract Number: 878 • 2018 ACR/ARHP Annual Meeting
IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome
Loïs BOLKO^1,2, Ségolène Toquet³, Océane Landon-Cardinal⁴, Karim DORGHAM⁵, Celine Anquetil⁶, Darragh Duffy⁷, Nadège WESNER⁸, Damien Amelin⁹, Gaëlle DZANGUE TCHOUPOU², Perrine Guillaume¹⁰, Aude Rigolet¹¹, Baptiste Hervier¹¹, Mathieu Vautier¹¹, Nicolas Champtiaux¹¹, Guy Gorochov¹², Jean-Hugues Salmon¹³, Olivier Benveniste¹¹ and Yves Allenbach¹⁴, ¹Rheumatology, CHU Reims, Hôpital Maison Blanche, Reims, France, ²INSERM UMRS974, Pitié-Salpêtrière University Hospital, Paris, France, ³Médecine interne, CHU Reims, Robert debré, Reims, France, ⁴Rhumatologie, Hopital Notre-Dame Montréal, Montreal, QC, Canada, ⁵CIMI, INSERM, Paris, France, ⁶CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ⁷Institut Pasteur, Paris, Paris, France, ⁸INSERM UMRS974, Pitié-Salpêtrière University Hospital, paris, France, ⁹Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ¹⁰Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié Salpêtrière, paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²CIMI, INSERM, paris, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Inflammatory idiopathic myopathies (IIM) is a heterogeneous group of disorders ranging from muscle specific auto-immune diseases to systemic ones (dermatomyositis (DM), anti-synthetase syndrome (ASS),…
Abstract Number: 879 • 2018 ACR/ARHP Annual Meeting
IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis
Nithin Reddy^1,2, Majid Zeidi³ and Victoria P. Werth⁴, ¹Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is an inflammatory myopathy where itch is a major contributor to impaired quality of life. Previously, we have shown that a cytokine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].